Ligobesy (Liraglutide)

Liraglutide mimics the natural hormone GLP‑1, binding to its receptor on pancreatic beta cells to increase insulin secretion only when glucose is elevated, while reducing glucagon release, slowing gastric emptying, and enhancing satiety signals in the brain.

The dose of Ligobesy is individualized by the prescribing healthcare professional. Initiation typically starts at a low dose that is gradually increased based on therapeutic response and tolerability, following the prescriber’s clinical judgment.

Safety of liraglutide during pregnancy and lactation has not been established. It should be avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under specialist guidance.

To order Ligobesy, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Ligobesy (liraglutide) shares the class‑wide benefits of GLP‑1 agonists, such as glucose‑dependent insulin release and appetite suppression. Compared with longer‑acting agents like semaglutide, liraglutide generally requires daily injections, while offering a well‑characterised safety profile and extensive clinical experience.

Ligobesy must be stored in a refrigerator at 2 °C to 8 °C. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to less than 30 °C for no more than 14 days.

Ligobesy is given as a subcutaneous injection, usually in the abdomen, thigh, or upper arm. Patients should follow the prescriber’s instructions on injection technique, rotate sites to reduce local reactions, and use the supplied pen or syringe device according to the manufacturer’s guidelines.

Serious adverse events include acute pancreatitis, gallbladder disease, severe hypoglycaemia (especially when combined with insulin or sulfonylureas), and, based on animal data, a potential risk of thyroid C‑cell tumours. Prompt medical evaluation is required if symptoms such as persistent abdominal pain, jaundice, or signs of an allergic reaction occur.

Ligobesy is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, those with multiple endocrine neoplasia type 2, and patients who are pregnant until safety is established. Caution is also advised for people with severe renal impairment or a history of pancreatitis.